New biomarkers of alcohol use disorders

The present invention relates to a method for predicting alcohol use disorder. The objective of this study was to validate the possibility of performing a plasma assay and to quantify the value of four plasmatic biomarkers of brain damage in patient with AUD, either at the onset of alcohol withdrawal in patients admitted for alcohol cessation or in abstinent patients with history of AUD. The inventors also 1) analysed the correlation between the levels of these biomarkers; 2) compared patients in alcohol cessation and abstinent patients; 3) analysed the association of these biomarkers, in alcohol cessation group, with the severity of alcohol withdrawal expressed by the dose of diazepam needed to control the signs of alcohol withdrawal the day after admission (D1) or the signs of neurologic severity of alcohol withdrawal on D1 expressed by WE’s symptoms. They showed that plasmatic Tau, NFL and UCHL1 are biomarkers of alcohol use disorders in alcoholic patients notably after cessation. Thus the invention relates a method for predicting alcohol use disorders (AUD) and their complications in a subject in need thereof comprising i) determining in a sample obtained from the subject the expression levels of at least one biomarker selected from the group consisting of Tau, NFL and UCHL1.

Keywords: Alcohol Use Disorder, Diagnosis, Prognosis, Blood Biomarker, Alcohol Withdrawal
Patent Application number: EP22 305 898.3 on 21/06/2022
Addict Biol 2022 Nov 27 Clergue-Duval et al Plasma tau NfL GFAP and UCHL1 as candidate biomarkers of alcohol withdrawal-associated brain damage: A pilot study doi: 10.1111/adb.13232.

You might also be interested in


Inserm Transfert

Research tool licensing team